- C4 Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- C4 Therapeutics Inc To Discuss CFT7455 Phase 1 Update Call TranscriptDec 12, 2023
- C4 Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 26, 2023
- C4 Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) - Panel Discussion TranscriptFeb 21, 2023
- C4 Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- C4 Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- C4 Therapeutics Inc at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- C4 Therapeutics Inc To Discuss CFT7455 Cohort Clinical Data Call TranscriptApr 08, 2022
- C4 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- C4 Therapeutics Inc CFT8919 Pre-Clinical Data Call TranscriptJun 07, 2021
- C4 Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- C4 Therapeutics Inc at UBS Global Healthcare Virtual Conference TranscriptMay 26, 2021
- C4 Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
C4 Therapeutics Inc CFT8919 Pre-Clinical Data Call Transcript
Good morning, everyone, and welcome to the C4 Therapeutics webcast to review new preclinical data for our EGFR degrader, CFT8919, being presented at the Keystone Symposium on Targeted Protein Degradation.
With me on the call today with prepared remarks are Andrew Hirsch, our Chief Executive Officer; and Dr. Adam Crystal, our Chief Medical Officer. Dr. Stew Fisher, our Chief Scientific Officer, will join for Q&A.
Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors including those set forth in the most recent filings with the SEC and any future filings that we may make with the SEC.
Following our prepared remarks, we will have time for a Q&A session. (Operator Instructions) With that, I'll turn the call over to Andrew.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)